Biocause Pharma(SZ:000627) 中国基金报·2025-07-01 06:31Core Viewpoint - The valuation of Tianmao Group has been drastically reduced by over 90% by Huitianfu Fund, reflecting severe market pessimism regarding the company's future prospects [2][3][10] Group 1: Valuation Adjustment - On July 1, Huitianfu Fund announced a new valuation for Tianmao Group at 0.27 CNY per share, down from 2.74 CNY per share prior to the suspension, marking a significant decline [2][4][7] - The adjustment was made in accordance with the guidelines from the China Securities Regulatory Commission regarding the valuation of securities investment funds [4][7] Group 2: Suspension and Reporting Issues - Tianmao Group's stock was suspended on May 6 due to its failure to disclose the 2024 annual report on time, with a warning of potential delisting if the report is not released within two months [8][9] - The company confirmed on April 30 that it could not meet the legal deadline for the 2024 report, leading to a significant drop in stock price and subsequent suspension [9][10] Group 3: Underlying Issues - The suspension is attributed to ongoing operational imbalances at its subsidiary, Guohua Life Insurance, which is facing liquidity pressures and deteriorating asset quality [9][10] - Industry insiders suggest that the company's inability to disclose financial reports is a critical indicator of its financial distress, with the risk of delisting becoming imminent [10]